Cipla
Andrew Hattendorf serves as Head of Market Access at Cipla USA since January 2023. Prior to this role, a notable tenure at Teva Pharmaceuticals spanned from October 2008 to October 2022, culminating in the position of Senior Director of Market Access, where Andrew led strategic initiatives regarding the implications of the Inflation Reduction Act on both commercial and government business channels. Additional roles at Teva included Director of Reimbursement Strategies in Oncology and Biosimilars, as well as Senior Field Reimbursement Manager, with recognition as a two-time Presidents Club Winner and recipient of the 2015 Market Access Achievement Award. Earlier career experiences encompass leadership positions at AccessMED/US Oncology, Pharmacia/Pfizer, and Schering Pharmaceuticals. Andrew holds a Bachelor's degree in Organizational Communication and Biology from the University of Colorado Boulder and a General Communication Bachelor's degree from St. Olaf College.
This person is not in the org chart
This person is not in any offices
Cipla
18 followers
Cipla is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.